Literature DB >> 27838214

Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review.

Rory Sheehan1, Angela Hassiotis2.   

Abstract

The use of antipsychotics to manage challenging behaviour in adults with intellectual disability is widespread but controversial, and evidence is scarce. There is a perception that antipsychotics used in this context can be reduced or discontinued, and this has been a major focus of recent national policy. However, such an intervention risks harm as well as having potential benefits. We reviewed the available evidence and found that antipsychotics can be reduced or discontinued in a substantial proportion of adults who use them for challenging behaviour, although not always without adverse effects. There is a group which displays behavioural deterioration on antipsychotic reduction that prevents discontinuation; predictors of poor response could not be reliably identified. In view of the relatively scarce data and methodological limitations of the available studies, we cannot draw firm conclusions to inform a population level approach to this issue. Antipsychotic medication used for behaviour should be reviewed regularly and an individualised approach taken to treatment.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2016        PMID: 27838214     DOI: 10.1016/S2215-0366(16)30191-2

Source DB:  PubMed          Journal:  Lancet Psychiatry        ISSN: 2215-0366            Impact factor:   27.083


  13 in total

1.  Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines.

Authors:  William F Sullivan; Heidi Diepstra; John Heng; Shara Ally; Elspeth Bradley; Ian Casson; Brian Hennen; Maureen Kelly; Marika Korossy; Karen McNeil; Dara Abells; Khush Amaria; Kerry Boyd; Meg Gemmill; Elizabeth Grier; Natalie Kennie-Kaulbach; Mackenzie Ketchell; Jessica Ladouceur; Amanda Lepp; Yona Lunsky; Shirley McMillan; Ullanda Niel; Samantha Sacks; Sarah Shea; Katherine Stringer; Kyle Sue; Sandra Witherbee
Journal:  Can Fam Physician       Date:  2018-04       Impact factor: 3.275

Review 2.  Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.

Authors:  Maire O'Dwyer; Philip McCallion; Mary McCarron; Martin Henman
Journal:  Ther Adv Drug Saf       Date:  2018-06-20

3. 

Authors:  William F Sullivan; Heidi Diepstra; John Heng; Shara Ally; Elspeth Bradley; Ian Casson; Brian Hennen; Maureen Kelly; Marika Korossy; Karen McNeil; Dara Abells; Khush Amaria; Kerry Boyd; Meg Gemmill; Elizabeth Grier; Natalie Kennie-Kaulbach; Mackenzie Ketchell; Jessica Ladouceur; Amanda Lepp; Yona Lunsky; Shirley McMillan; Ullanda Niel; Samantha Sacks; Sarah Shea; Katherine Stringer; Kyle Sue; Sandra Witherbee
Journal:  Can Fam Physician       Date:  2018-04       Impact factor: 3.275

4.  Changes in Stereotypical Behavior Following Chlorpromazine Termination: Polypharmcy Effects on Response Class Membership.

Authors:  Maria G Valdovinos; Marisela Aguilar; Drew Piersma; Alyssa Wilkinson; Craig H Kennedy
Journal:  Adv Neurodev Disord       Date:  2020-05-20

5.  Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study.

Authors:  Rory Sheehan; Laura Horsfall; André Strydom; David Osborn; Kate Walters; Angela Hassiotis
Journal:  BMJ Open       Date:  2017-08-03       Impact factor: 2.692

6.  Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities.

Authors:  Yona Lunsky; Wayne Khuu; Mina Tadrous; Simone Vigod; Virginie Cobigo; Tara Gomes
Journal:  Can J Psychiatry       Date:  2017-08-22       Impact factor: 4.356

7.  Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study.

Authors:  Tara Gomes; Wayne Khuu; Mina Tadrous; Simone Vigod; Virginie Cobigo; Yona Lunsky
Journal:  BMJ Open       Date:  2019-07-30       Impact factor: 2.692

8.  Support staff's perceptions of discontinuing antipsychotics in people with intellectual disabilities in residential care: A mixed-method study.

Authors:  Bas Kleijwegt; Addy Pruijssers; Lydie de Jong-Bakker; Koos de Haan; Harmieke van Os-Medendorp; Berno van Meijel
Journal:  J Appl Res Intellect Disabil       Date:  2019-02-20

9.  De-Prescribing of Psychotropic Medications in the Adult Population with Intellectual Disabilities: A Commentary.

Authors:  Bernadette Flood
Journal:  Pharmacy (Basel)       Date:  2018-03-30

10.  Anticholinergic burden in adult and elderly people with intellectual disabilities: Results from an Italian multicenter cross-sectional study.

Authors:  Luc Pieter De Vreese; Ulrico Mantesso; Elisa De Bastiani; Annachiara Marangoni; Elisabeth Weger; Tiziano Gomiero
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.